IL-4 Receptor Antibody Engineering for Selective Allergy Pathway Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, such as asthma, allergic rhinitis, and atopic dermatitis, are limited in efficacy and specificity, particularly targeting the IL-4R pathway, which plays a crucial role in these conditions.
Innovation Solution
Development of a specific antibody that binds to the IL-4R, blocking IL-4 interaction and modulating immune responses, utilizing optimized light and heavy chain variable regions with defined CDR sequences to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for allergic diseases are used, then they provide general anti-inflammatory effects, but they lack specificity and have limited efficacy in targeting the IL-4R pathway
Solution Approach 1:
The patent applies local quality by designing an antibody that specifically targets the IL-4Rα chain, concentrating therapeutic action at the specific molecular level rather than providing general anti-inflammatory effects. The antibody's variable region is engineered to recognize and bind specifically to the IL-4Rα chain, providing localized and specific inhibition of the IL-4 signaling pathway while leaving other immune pathways unaffected.
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequence of the antibody's variable region to optimize binding affinity and specificity for the IL-4Rα chain. The CDR sequences are specifically designed with certain amino acid compositions and structures that enhance the antibody's ability to selectively bind to IL-4Rα, changing the parameters of molecular recognition and interaction.
2Reliability
If a specific antibody targeting IL-4Rα is developed, then therapeutic efficacy and specificity are improved, but the complexity of the treatment increases
Solution Approach 1:
The patent applies the taking out principle by isolating and targeting specifically the IL-4Rα chain component of the broader IL-4 signaling system. Rather than attempting to modulate the entire immune response or target multiple receptors simultaneously, the invention extracts and addresses the specific IL-4Rα chain as the critical therapeutic target, simplifying the treatment approach while maintaining high specificity.
3Reliability
If the antibody binds strongly to IL-4R, then it effectively blocks IL-4 signaling, but it may also affect binding of other cytokines that share the receptor
Solution Approach 1:
The patent applies local quality by designing the antibody to recognize a specific epitope on the IL-4Rα chain that is critical for IL-4 binding but less critical for IL-13 binding. This localized targeting approach allows the antibody to selectively block IL-4 signaling while preserving IL-13 signaling, achieving both high blocking efficacy and selectivity through precise molecular recognition.
Data Source
AI summary
Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.